Focus: BrainStorm Cell Therapeutics is a New York-based public biotech focused on autologous adult stem cell therapy, specifically developing cell-based treatments for neurological diseases like ALS and MS.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow BrainStorm Cell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for BrainStorm Cell Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BrainStorm Cell Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant - Stock Titan
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing - Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing Stock Titan
BrainStorm Cell Therapeutics Proposes FDA Regulatory Reforms for ALS and Regenerative Medicine Clinical Trials - geneonline.com
BrainStorm Cell Therapeutics Proposes FDA Regulatory Reforms for ALS and Regenerative Medicine Clinical Trials geneonline.com
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - Yahoo Finance
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine Yahoo Finance
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay - Stock Titan
BrainStorm (BCLI) CEO granted 1.8M restricted stock units as equity pay Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant - Stock Titan
BrainStorm Cell (BCLI) EVP Uri Yablonka awarded 150,000 RSUs in new grant Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo